Efficacy of rasburicase therapy in obstructive renal failure secondary to urolithiasis: A novel therapeutic option;Eficacia de la rasburicasa en el fracaso renal agudo obstructivo por litiasis: Una nueva opción terapéutica

Nefrologia

Volumn 28, Issue 1, 2008, Pages 102-105

  Segura Torres, Pilar ^a,b   Borrego Utiel, F J ^a   Perez Del Barrio P ^a   Gil Cunquero, J M ^a   Perez Banasco V ^a  

^a Servicio de Nefrologia

^b Complejo Hospitalario de Jaén ^*  (Spain)

Author keywords

Nephrolithiasis; Obstructive acute renal failure; Rasburicase; Uric acid

Indexed keywords

RASBURICASE; URATE OXIDASE;

ADULT; AGED; ARTICLE; CASE REPORT; HUMAN; KIDNEY FAILURE; MALE; NEPHROLITHIASIS;

ADULT; AGED; HUMANS; KIDNEY CALCULI; KIDNEY FAILURE; MALE; URATE OXIDASE;

EID: 47049124291     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, Van den Berg H. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with Cancer: report of an international compassionate use study. Cancer 98 (5): 1048-54, 2003.
2. Zaidi S, Aljurf M. Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies? Journal of Clinical Oncology 22 (16): 3430-3431, 2004.
3. Viedma G, Borrego FJ, Pérez del Barrio P, De Santi C. Resolución rápida de fracaso renal agudo tras uso de rasburicasa en síndrome de lisis tumoral. Nefrología 25 (5): 572-573, 2005.
4. Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 20: 431-433, 2005.
5. Moolenburgh JD, Reinders MK, Jansen Tl. Rasburicase treatmente in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 25 (5): 749-752, 2006.
6. Vogt B, Gugger M, Frey FJ. Rasburicase (Fasturtec). Ther Umsch 61 (9): 579-582, 2004.
7. Fam Ag. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep 3 (1): 29-35, 2001.
8. De Bont JM, Pieters R. Management of hyperuricemia with rasburicase review. Nucleosides Nucleotides Nucleic Acids 23 (8-9): 1431-1440, 2004.
9. Klahr S. Urinary Tract Obstruction. En: Schrier RW editor. Diseases of the kidney and urinary tract. Philadelphia, PA: Lippincott Williams and Wilkins pp. 757-787, 2001.
10. Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 44 (5): 799-805, 2004.
11. Kim MS, Corwin HL. Urinalysis. En: Schrier RW editor. Diseases of the kidney and urinary tract. Philadelphia, PA: Lippincott Williams and Wilkins pp. 317-331, 2001.
12. Arrizabalaga P. El diafragma de filtración glomerular. Orientación diagnóstica y terapéutica en el síndrome nefrótico. Nefrología 25 (4): 361-368, 2005.
13. Norden A, Lapsley M, Lee P, Pusey C, Scheinman S, Tam F, Thakker R, Unwin R, Wrong O. Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney International 60: 1885-1892, 2001.
14. Ronco C, Inguaggiato P, Bordoni V, De Cal M, Bonello M, Andrikos E, Assuman Y, Rattanarat R, Bellomo R. Rasburicase therapy in acute hyperuricemia and renal dysfunction. Contrib Nephrol 147: 115-123, 2005.